Showing 5211-5220 of 5758 results for "".
- Galderma Launches Three New DTC Campaignshttps://practicaldermatology.com/news/galderma-launches-three-new-dtc-campaigns/2458673/Galderma is rolling out three new direct-to-consumer creative campaigns designed to educate consumers and support Dysport® and Restylane® Silk. The campaigns, which feature unretouched photography, will be supported by significant print,
- Provectus Biopharmaceuticals Announces Leadership Changeshttps://practicaldermatology.com/news/provectus-biopharmaceuticals-announces-leadership-changes/2458674/Provectus Biopharmaceuticals, Inc. detailed several leadership changes following the resignation of one of its Co-Founders and its Chairman and CEO, H. Craig Dees, PhD. The Provectus Board of Directors accepted the resignation of Dr. Dees, which he submitted due to personal and health reasons, in
- Valeant Dermatology Launches Aspire Higher Scholarship Programhttps://practicaldermatology.com/news/valeant-dermatology-launches-aspire-higher-scholarship-program/2458676/Valeant Dermatology, a division of Valeant Pharmaceuticals North America LLC, launched Valeant Dermatology ASPIRE HIGHER Scholarship Program that will award scholarships of up to $10,000 each to nine individual students who will be attending an undergraduate or graduate education program during t
- Valeant Pharmaceuticals Announces Management And Business Updatehttps://practicaldermatology.com/news/valeant-pharmaceuticals-announces-management-and-business-update/2458677/J. Michael Pearson has returned as Valeant Pharmaceuticals International, Inc.’s chief executive officer following his recovery from severe pneumonia and other complications. Howard B. Schiller, Valeant's interim chief executive officer, will transition out of his current duties but wil
- Galderma to Begin Two Phase III Restylane Trialshttps://practicaldermatology.com/news/galderma-to-begins-two-phase-iii-restylane-trials/2458679/Galderma is set to initiate a pivotal Phase III trial on Restylane® Lyft for hand augmentation and another that will look to the safety of Restylane® Silk when ad
- Pioneer in Laser Development to Give Keynote at ASLMS 2016https://practicaldermatology.com/news/pioneer-in-laser-development-to-give-keynote-at-aslms-2016/2458682/Robert Afzal, PhD, a leading expert in high power fiber laser development, will deliver the keynote address at ASLMS 2016, the Annual Conference of the American Society for Laser Medicine & Surgery, Inc. (ASLMS), to be held in Boston, Massachusetts March 30 – April 2, 2016. Dr. Afzal wi
- Neutrogena® Launches First-Ever Global Beauty Campaignhttps://practicaldermatology.com/news/neutrogena-launches-first-ever-global-beauty-campaign/2458684/Neutrogena® is set to debut their first-ever global campaign: “Neutrogena. See What’s Possible.™” A commercial voiced by Brand Ambassador and creative consultant Kerry Washington will fe
- Galderma Mans Up with New Cetaphil Line for Menhttps://practicaldermatology.com/news/cetaphils-newest-line-targets-men/2458690/Galderma Laboratories, L.P is manning up with the launch of a new skin care line for men. The Cetaphil® Men line comprises Cetaphil® Men Daily Face Wash, Cetaphil® M
- New AAD Acne Guidelines Call for Combination Therapyhttps://practicaldermatology.com/news/new-aad-acne-guidelines-call-for-combination-therapy/2458695/Combination therapy is the way forward for treating moderate-to-mild acne, according to new guidelines from The American Academy of Dermatology. For example, antibiotics should be used with topical acne therapy, and patients should continue using topical treatments to manage their c
- Caladrius Biosciences Licenses Dermatology Cell Technology to AiVita Biomedicalhttps://practicaldermatology.com/news/caladrius-biosciences-licenses-dermatology-cell-technology-to-aivita-biomedical/2458698/Caladrius Biosciences, Inc., has licensed exclusive global rights to its cell-derived dermatological technology for topical skin applications to AiVita Biomedical, Inc. The company says this transaction supports its strategy to monetize non-core assets. AiVita, a biotechnology company, wa